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Abstract 
Background: This cross‑sectional analysis evaluated whether determination of E‑selectin concentrations could iden‑
tify deterioration of cardiometabolic risk profile or subclinical atherosclerosis in individuals at low‑to‑moderate risk 
included in The Brazilian Longitudinal Study of Adult Health—ELSA‑Brasil.
Methods: A sample of 984 individuals from ELSA‑Brasil (35–54 years) without cardiovascular disease or diabetes was 
stratified according to E‑selectin tertiles. Traditional risk factors, inflammatory markers and categories of coronary 
artery calcium (CAC) scores were evaluated across the tertiles by ANOVA or Chi‑squared test. In linear regression mod‑
els, associations of E‑selectin levels with insulin resistance index, adjusted for age, sex and adiposity were tested.
Results: The mean age of the participants was 45.8 (SD 4.9) years and 55 % were women. Mean values of age, 
anthropometric data, biochemical variables and inflammatory status increased across E‑selectin tertiles. Also, a grad‑
ual deterioration of the cardiometabolic profile was reflected by increments in frequencies (95 % CI) of BMI ≥ 25 kg/
m2 [53.7 % (48.5–58.8), 61.0 % (56.1–66.5) and 64.2 % (59.0–69.4), p = 0.019], hypertension [18.0 % (14.1–22.8), 19.8 % 
(15.4–24.6) and 24.8 % (20.4–29.9), p = 0.048], pre‑diabetes [62.5 % (57.4–68.3), 63.1 % (58.4–69.6) and 73.8 % (68.8–
78.3), p = 0.003] and hypertriglyceridemia [22.4 % (17.9–27.2), 27.3 % (22.5–32.8) and 33.4 % (28.3–38.5), p = 0.013]. 
Insulinemia and HOMA‑IR were independently associated with E‑selectin concentration. A greater proportion of indi‑
viduals with CAC scores different from zero was found in the third tertile when compared with the first and second 
tertiles (16.1 versus 11 %, p = 0.04, respectively).
Conclusions: Direct associations of E‑selectin with traditional risk factors slightly above their normal ranges, compo‑
nents of the metabolic syndrome, insulin resistance and presence of CAC suggest that this biomarker may indicate an 
initial atherogenic process.
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Background
Metabolic disorders such as type 2 diabetes mellitus 
(T2DM) and cardiovascular diseases (CVD) are major 
causes of death worldwide [1]. Despite some decrease in 
mortality rates, attributed to the control of risk factors 
(smoking, physical inactivity, elevated blood pressure and 
lipids and glucose levels), CVD is still the leading cause 
of disability adjusted life years in many developed and 
developing countries [2, 3].
Traditional cardiovascular risk factors are commonly 
clustered and insulin resistance is a pathophysiologi-
cal link [4]. Low-grade inflammation and endothelial 
dysfunction are also involved in the insulin resistance 
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syndrome. Both abnormalities are present in atheroscle-
rosis and precede the development of T2DM [5, 6]. Some 
soluble molecules may be detected in circulation before 
these outcomes, which could represent an opportunity to 
identify atherogenesis prior to abnormalities in the tra-
ditional cardiometabolic risk profile [7, 8]. An early step 
in atherogenesis is the leukocytes adhesion to endothe-
lium, triggered by a number of molecules, expressed in 
endothelial cells, that can be measured in circulation [9, 
10]. Among those, the selectin family was shown to par-
ticipate in this process [11] and has been associated with 
CVD and T2DM [7, 11, 12], but with the cardiometabolic 
profile particularly among low-to-moderate risk individ-
uals has been less investigated.
The Longitudinal Study of Adult Health—ELSA-Brasil 
is a multicenter cohort study, including 15,105 active or 
retired employees of 6 Brazilian universities, aged 35–74, 
which will permit innovative investigation of multiple 
exposures and outcomes, particularly T2DM and cardio-
vascular events [13, 14]. This study offers an opportunity 
to examine novel circulating biomarkers of inflamma-
tion and atherogenesis that might be useful to further 
improvement in risk level detection. A subset of ELSA-
Brasil participants was selected to assess the association 
of E-selectin with traditional risk factors as well as with 
structural lesion of atherosclerosis. We hypothesized that 
increased concentrations of E-selectin could be associ-
ated with the gradual progression of cardiometabolic risk 
profile in a subset of individuals at low-to-moderate risk.
Methods
This cross-sectional study was conducted in a subset of 
the participants of one ELSA-Brasil center, the Univer-
sity of São Paulo, in Sao Paulo city. First examinations 
of 5056 individuals of ELSA-Sao Paulo were carried out 
from 2008 to 2010. For the purpose of the present analy-
sis, after excluding diabetes and cardiovascular disease, a 
sample of 1000 individuals, aged 35–54  years, was ran-
domly selected from the participants of São Paulo [15, 
16], keeping the same proportions of sexes within the age 
groups (35–44 and 45–54 years) found in the main study. 
A total of 984 individuals with E-selectin determination 
were enrolled in this analysis. The institutional ethics 
committee approved the study and written consent was 
obtained from all individuals.
Participants had an initial interview using standard-
ized questionnaires and then scheduled for physical 
examination and laboratory tests at the University Hos-
pital. Body weight and height were measured using cali-
brated electronic scales and a fixed rigid stadiometer, 
while individuals wore light clothing without shoes. Body 
mass index (BMI) was calculated as weight (kilograms) 
divided by squared height (meters). Waist circumference 
was measured with an inextensible tape according to the 
WHO technique. Blood pressure (BP) was taken three 
times after a 5-min rest in the sitting position. The mean 
of the second and third measurements were used in the 
analyses.
After overnight fasting, blood samples were taken for 
several determinations. They underwent a 2-h 75-g oral 
glucose tolerance test. American Diabetes Association 
criteria were used to define categories of glucose toler-
ance, considering pre-diabetic those with impaired fast-
ing glycemia (fasting plasma glucose ≥100 and <126 mg/
dL and 2-h plasma glucose <140 mg/dL) and/or impaired 
glucose tolerance (2-h plasma glucose ≥140  mg/dL and 
<200  mg/dL and fasting plasma glucose <126  mg/dL) 
(ADA). Metabolic syndrome was defined by the presence 
of any three of the following components, according to 
international consensus criteria [17]:
  • waist circumference ≥94 cm for men and ≥80 cm for 
women;
  • systolic BP ≥130 or diastolic BP ≥85 mmHg (or anti-
hypertensive treatment);
  • fasting plasma glucose ≥100 and <125 mg/dL in the 
absence of antidiabetic agents;
  • triglyceride concentration ≥150  mg/dL (or specific 
treatment);
  • HDL-cholesterol <40 mg/dL for men and <50 mg/dL 
for women (or specific treatment).
Samples were immediately centrifuged and analyzed. 
Plasma glucose was measured by the hexokinase method 
(ADVIA Chemistry; Siemens, Deerfield, Illinois, USA). 
Total cholesterol was assessed by cholesterol oxidase 
method, enzymatic colorimetric, HDL-cholesterol by 
homogeneous colorimetric, without precipitation, tri-
glycerides by enzymatic colorimetric (ADVIA Chemis-
try; Siemens, Deerfield, Illinois, USA); the low-density 
lipoprotein cholesterol concentrations were calculated 
by the Friedewald equation. When triglyceride concen-
tration was greater than 400  mg/dL, the high-density 
lipoprotein cholesterol level was directly measured [18]. 
Aliquots were frozen at −80  °C for further determina-
tions of hormones, apolipoproteins, markers of inflam-
mation and adhesion molecule.
Insulin was determined by enzyme-linked immu-
noenzymatic assay—ELISA (Siemens, Tarrytown, USA). 
Homeostasis model assessment (HOMA-IR) was used 
to evaluate insulin resistance [19]. ELISA kits were also 
used for the determination of high-sensitivity C-reactive 
protein by immunochemistry (Dade Behring, Siemens, 
Marburg, Germany) and E-selectin (Abnova Corp, Tai-
pei, Taiwan). Interleukin-6 (IL-6), interleukin-10 (IL-10) 
and tumor necrosis factor α (TNF-α) were determined by 
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the Bio-Plex® Pro Human Cytokine multiplex assay panel 
(Biorad, São Paulo, SP, Brazil). Intra-assay coefficients of 
variation ranged from 1.8 to 7.2. Inter-assay coefficients 
varied from 0.9 to 9.1, except for E-selectin (14.4 %). Sub-
clinical inflammatory status was assessed through the 
ratio of pro-inflammatory and anti-inflammatory bio-
markers, being IL-6/IL-10 and TNF-α/IL-10 ratios [20].
Results of coronary artery calcium score scanning were 
available for 947 individuals. They underwent ECG-gated 
unenhanced computed tomography to calculate CT cal-
cium score measured according to Agatston et  al. [21]. 
Analysis of coronary artery calcium was performed on 
a post processing workstation using dedicated CT cal-
cium score analysis software. CAC was calculated and 
expressed as Agatston scores for standard of reference 
CT calcium score. Coronary artery calcium (CAC) score 
was categorized based as CAC = 0, 1–10 (mild), 11–100 
(moderate), >100 (severe) [22, 23].
Statistical analysis
Data are expressed as means and standard deviations 
(SD) or as medians and interquartile intervals. Distri-
butions of some variables were skewed and thus were 
log-transformed before analysis to achieve normality. 
Values in tables were back-transformed to return to the 
natural scale. Participants were categorized into tertiles 
of E-selectin concentration to test its association with 
traditional cardiovascular risk factors, insulin resist-
ance, inflammatory markers and CAC Agatston score. 
Data were compared by ANOVA with Bonferroni cor-
rection to identify the significant differences, which were 
marked with symbols. Frequencies were compared by 
Chi squared test and 95 % confidence intervals (95 % CI) 
were shown. Linear regression models were performed 
to evaluate independent associations of E-selectin lev-
els with indices of insulin resistance, adjusted for age, 
sex and adiposity. Sensitivity analyses, excluding par-
ticipants who were current smokers, were conducted to 
assess influence on variables. As results did not change, 
data from all the participants were shown. All statistical 
analyses were performed using the Statistical Package for 
Social Sciences, v. 19.0 for Windows (SPSS Inc., Chicago, 
Illinois, USA). A p value <0.05 was considered significant.
Results
The mean age of the 998 participants was 45.8 (SD 4.9) 
years and 55  % were women. Nineteen percent had 
BMI ≥30 kg/m2 and 66 % were pre-diabetic. The majority 
of the sample (59 %) had at least 1 or 2 risk factors and 
20 % were classified as having metabolic syndrome.
Decreasing proportions of women were observed 
across E- selectin tertiles, while mean values of age, 
anthropometric and biochemical variables increased 
(Table 1). Although the CRP did not differ across E-selec-
tin tertiles, inflammatory status (assessed by the ratios of 
pro- and anti-inflammatory biomarkers) changed signifi-
cantly across these categories.
Figure  1 depicts the frequencies of traditional cardio-
vascular risk factors according to tertiles of E-selectin 
concentrations. The cardiometabolic profile showed 
a progressive deterioration across tertiles reflected by 
the differences in the mean frequencies (95  % CI) of 
BMI ≥25  kg/m2 [53.7  % (48.5–58.8), 61.0  % (56.1–66.5) 
and 64.2 % (59.0–69.4), p = 0.019], hypertension [18.0 % 
(14.1–22.8), 19.8  % (15.4–24.6) and 24.8  % (20.4–29.9), 
p 0.048], pre-diabetes [62.5 % (57.4–68.3), 63.1 % (58.4–
69.6) and 73.8  % (68.8–78.3), p  =  0.003] and hypertri-
glyceridemia [22.4 % (17.9–27.2), 27.3 % (22.5–32.8) and 
33.4  % (28.3–38.5), p  =  0.013], resulting in increasing 
proportions of individuals with the metabolic syndrome 
from the first to the second and third tertile of E-selectin 
[18.6 % (14.4–23.1), 19.5 % (15.0–24.2) and 28.3 % (23.6–
33.4), p = 0.007, respectively].
In multiple linear regression analysis, the insulin resist-
ance index HOMA-IR was independently associated 
with E-selectin concentrations, adjusted for sex and BMI 
(Table 2). When fasting insulin entered the model instead 
of HOMA-IR, the results did not change, showing its 
independent association with E-selectin. In both cases, 
the significant associations persisted when adjusted for 
waist circumference instead of BMI (data not shown).
Considering frequencies of CAC score categories, the 
third tertile of E-selectin levels had a greater propor-
tion of individuals with CAC score different from zero 
or greater than 10 (Table 3). CAC score greater than 100 
score was found in only 4.0 % (n = 12) of the participants 
of the third tertile and in 2.4 % (n = 14) of those included 
in first or second tertiles (p = 0.175).
Discussion
The present study calls attention to the potential role of 
E-selectin concentration for earlier identification of the 
atherosclerotic process, since its circulating levels were 
shown to be associated with gradual deterioration of tra-
ditional risk factors (blood pressure, lipids and plasma 
glucose) even within near-normal ranges. Associations of 
E-selectin with components of the metabolic syndrome 
as well as with insulin resistance reinforce such state-
ment. Despite the low frequency of structural coronary 
lesions in our sample, the presence of calcium in coro-
nary arteries was also associated with higher E-selectin 
concentrations.
The rationale of examining adhesion molecule in mid-
dle-aged adults without T2DM or CVD took into consid-
eration that novel circulating biomarkers of inflammation 
and atherogenesis might be useful to improve detection 
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of risk level in further analyses [11, 24–27]. Although this 
study did not address cardiovascular risk stratification, 
clarifying the associations of these biomarkers in low-to-
moderate risk condition could base future longitudinal 
analyses with such purpose.
Adhesion molecules, like selectins and CAMs, are 
stimulated by metabolic disturbances and their role for 
the development of the arterial plaque is recognized [10–
12]. Although selectin has a major effect on endothelium 
activation, other tissues also express this molecule [10, 
28]. At least in part, E-selectin is stimulated by inflam-
matory cytokines [29–31], which could explain the par-
allelism between TNF-α and E-selectin concentrations 
with the worsening of the metabolic profile observed in 
our study. Particularly, transcription of E-selectin occurs 
only on the endothelial cell surface, promoting leukocyte 
adhesion and migration to the subendothelial region, 
which triggers inflammatory response. In agreement with 
this underlying mechanism, in our study, inflammatory 
indexes (IL-6/IL-10 and TNF-α/IL-10 ratios), but not 
CRP, increased significantly across the tertiles of E-selec-
tin. It is possible that low-grade inflammation detectable 
by CRP levels may be found in individuals at a higher car-
diometabolic risk than those participants of the present 
study.
The progressive deterioration of traditional cardiovas-
cular risk factors within near-normal values, in parallel 
with elevation of E-selectin concentration, could suggest 
the utility of this biomarker in identifying earlier abnor-
malities in cardiometabolic risk profile [10]. In previous 
cross-sectional study, our group reported a direct asso-
ciation of E-selectin and other inflammatory biomarkers 
with worsening of the glucose metabolism [32]. Although 
our study design precludes establishing cause-effect rela-
tionship, the observations of increasing frequencies of 
components of the metabolic syndrome across E-selectin 
tertiles are in agreement with this hypothesis. Actually, in 
a prospective study, endothelial dysfunction was shown 
to predict T2DM in women, independent of other risk 
factors [7].
Table 1 Number (% in parenthesis) or mean values (SD) of clinical variables including circulating biomarkers of a subset 
of ELSA-Brasil participants, according to tertiles of E-selectin
Values are means (SD) or medians (interquartile intervals), except for number of women (%) and for HbA1c reported in % (mmol/mol). SD for HbA1c was 0.6, 0.5 and 
0.6 % for tertiles 1, 2 and 3 respectively
Il interleukin, TNF-α tumor necrosis factor‑alpha
a p for trend or linear by linear
b p value obtained by Chi squared test or ANOVA with Bonferroni correction
c Tertile 1 versus Tertile 3
d Tertile 2 versus Tertile 3
e Tertile 1 versus Tertile 2
f Log‑transformed variables for analysis
Tertile1 
N = 328 (4.6–55.3 ng/mL)
Tertile 2 
N = 328 (55.4–99.2 ng/mL)
Tertile 3 
N = 328 (≥99.2 ng/mL)
p valueb p valuea
Women, n (%) 196 (59.8) 180 (54.9) 170 (48.8) 0.01 0.005
Age (years) 45.3 (5.0) 46.0 (4.7) 45.8 (4.9) 0.616 0.743
Body mass index (kg/m2) 25.9 (3.9) 26.1 (4.1) 27.2 (4.3) <0.001c, d <0.001
Waist circumference (cm) 85.0 (10.9) 86.1 (11.4) 90.0 (11.5) <0.001c, d <0.001
Systolic blood pressure (mmHg) 115.4 (14.2) 115.8 (13.9) 119.4 (15.2) <0.001c, d <0.001
Diastolic blood pressure (mmHg) 73.8 (10.1) 74.2 (10.3) 77.3 (10.6) <0.001c, d <0.001
Fasting plasma glucose (mg/dL) 102.3 (13.3) 101.9 (8.2) 103.9 (8.0) <0.026d 0.037
2‑hour plasma glucose (mg/dL) 118.5 (25.7) 121.6 (25.2) 122.1 (27.3) 0.170 0.082
HbA1c  % (mmol/mol) 5.2 [32] 5.1 [31] 5.4 (36) <0.001c, d, e 0.011
Total cholesterol (mg/dL) 205.4 (36.2) 208.2 (36.1) 215.0 (37.2) 0.003d 0.001
LDL‑cholesterol (mg/dL) 126.9 (30.4) 127.3 (31.7) 132.7 (33.5) 0.037 0.021
HDL‑cholesterol (mg/dL) 55.7 (13.4) 56.0 (13.6) 54.0 (12.6) 0.130 0.170
Triglycerides (mg/dL) 115.1 (64.4) 126.6 (71.5) 142.8 (89.1) <0.001c, d <0.001
Fasting insulinf (µUI/ml) 5.7 (4.4) 7.7 (5.6) 8.5 (6.9) <0.001d, f <0.001
HOMA‑IR 1.4 (1.2) 2.0 (1.5) 2.2 (1.8) <0.001d, e <0.001
C‑reactive proteinf (mg/L) 1.2 (0.6–2.3) 1.1 (0.6–2.7) 1.3 (0.7–3.0) 0.244 0.122
IL‑6/IL‑10 4.3 (3.0–5.8) 4.4 (3.2–5.8) 4.6 (3.7–5.8) 0.010c 0.003
TNF‑α/IL‑10 2.7 (3.0–4.9) 3.7 (3.1–4.5) 3.8 (3.3–4.7) 0.044c 0.012
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Considering that insulin resistance is the central abnor-
mality of the metabolic syndrome, we tested association 
of E-selectin with insulinemia and with HOMA-IR in 
multiple regression analyses. Associations of E-selectin 
with insulin resistance persisted after adjustment for sex 
and body adiposity. Along the same line, insulin sensitiv-
ity, as assessed by hyperinsulinemic euglycemic clamp, 
was found to be negatively correlated to E-selectin levels 
[8]. In addition, our data are in agreement with a study 
conducted in healthy subjects, in which adhesion mol-
ecules were associated with body mass and insulin resist-
ance indexes [33].
Our findings were obtained in a large sample of mid-
dle-aged individuals whose body adiposity was near-
normal, but their BMI and waist circumference gradually 
increased across E-selectin categories. There is some 
evidence that adipocyte-derived pro-inflammatory 
cytokines activate the production of endothelium pro-
teins inducing insulin resistance [34]. A positive asso-
ciation of E-selectin with the insulin resistance index 
persisted even after adjusting for BMI. Therefore, we 
speculate that determination of E-selectin in blood could 
be useful to detect not only endothelium dysfunction 
but also a condition of insulin resistance independent of 
obesity.
Our observation of an association of HOMA-IR 
with E-selectin values reinforces a role of insulin resist-
ance for atherosclerosis [5]. The present study had the 
opportunity of evaluating structural coronary lesions 
by computed tomography in a sub-sample of the ELSA-
Brasil participants. CAC score has been recognized as 
an accurate method to detect coronary damage and pre-
dict events [21–23]. Due to the clinical characteristics of 
our participants, most had negative results for the pres-
ence of calcium in coronary arteries (CAC score equal 
to zero), which limited assessment of its trend across 
tertiles of E-selectin. Combining tertiles 1 and 2, we 
observed that the number of CAC scores different from 
zero was fewer than those in the third tertile. Consider-
ing the importance of E-selectin on the atherosclerotic 
process, our results may motivate further investigation of 
its potential as an earlier marker that could be a target for 
primary prevention. The cohort of ELSA-Brasil will per-
mit not only being able to confirm these associations, but 
will provide the opportunity to investigate prospectively 
the impact of the exposure to this biomarker and others 
on several outcomes [13].
Our study has the strength of measuring this endothe-
lium adhesion molecule in association with cardiometa-
bolic risk factors and CAC score in a big sample size of 
middle-aged individuals at low-to-moderate risk. Other 
parameters of low-grade inflammation and insulin were 
also available. A limitation is related to the cross-sec-
tional design that impedes inference of causality. A large 
inter-individual variability was observed similar to previ-
ously described.
Fig. 1 Frequencies (%) of traditional cardiovascular risk factors in a 
subset of ELSA‑Brasil participants according to E‑selectin tertiles. BMI 
body mass index (kg/m2). Pre‑diabetes, impaired fasting glycemia 
(fasting plasma glucose ≥100 and <126 mg/dL and 2‑h plasma 
glucose <140 mg/dL) and/or impaired glucose tolerance (2‑h 
plasma glucose ≥140 and <200 mg/dL and fasting plasma glucose 
<126 mg/dL) (ADA). Hypertension, systolic BP ≥130 or diastolic 
BP ≥85 mmHg (or antihypertensive treatment). High triglyceride, 
triglyceride concentration ≥150 mg/dL (or specific treatment). Low 
HDL‑cholesterol, HDL‑cholesterol <40 mg/dL for men and <50 mg/dL 
for women (or specific treatment)
Table 2 Final model of  multiple linear regression for  the 
association of  E-selectin concentration (dependent vari-
able) with insulin resistance index
Model adjusted for age (non‑significant association)
CI confidence interval
β 95 % CI p value
Insulin resistance index 4.424 1.662–7.187 0.002
Sex (male) 10.347 3.054–17.639 0.005
Body mass index 1.200 0.188–2.213 0.020
Table 3 Number of participants (%) in tertiles of E-selectin 
according to  categories of  coronary artery calcium (CAC) 
score
Chi square test was used
Tertiles 1 + 2
N = 585
Tertile 3 
N = 298
p value
CAC score > zero (%) 70 (11.4) 51 (16.1) 0.042
CAC score >10 (%) 46 (7.9) 36 (12.1) 0.041
CAC score >100 (%) 14 (2.4) 12 (4.0) 0.175
Page 6 of 7de Almeida‑Pititto et al. Diabetol Metab Syndr  (2016) 8:19 
Conclusions
In summary, the findings of direct associations of E-selec-
tin with traditional risk factors slightly above their nor-
mal ranges, with components of the metabolic syndrome, 
insulin resistance and CAC scores different from zero 
suggest that this biomarker could be indicating initial ath-
erogenic process. The utility of E-selectin determination 
for the improvement of cardiovascular risk prediction 
deserves further investigation in longitudinal studies.
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